Ta and T1 Bladder Cancer: Location, Recurrence and Progression†

Heney, Niall M.; Nocks, Barry N.; Daly, James J.; Prout, George R.; Newall, Joseph; Griffin, Pamela P.; Perrone, Theresa; Szyfelbein, Wanda A.

doi:10.1111/j.1464-410x.1982.tb13538.x

Cited by 162 publications

(65 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21 A few small studies have demonstrated that positive urine cytology in patients with superficial (Ta or T1) tumors is associated with disease recurrence, suggesting that urine cytology perhaps does have a role to play in prognostication. 11,13,14 However, none demonstrated an association of urine cytology with disease progression. Further, those studies included patients who had high-grade tumors, a known independent risk factor for recurrence and progression.…”

Section: Discussionmentioning

confidence: 99%

Cytologic and cystoscopic predictors of recurrence and progression in patients with low‐grade urothelial carcinoma

Jackson

Barkan

Kapur

et al. 2013

Cancer Cytopathology

View full text Add to dashboard Cite

BACKGROUND:Patients with low-grade urothelial carcinoma (LGUC) are at risk of recurrence and must undergo lifelong surveillance. To date, cytology and cystoscopy are the gold standard for the detection of de novo and recurrent LGUC.The objective of the current study was is to further characterize the role of cytology and cystoscopy in determining the risk of recurrence and progression in these patients. METHODS: The authors retrospectively identified patients with LGUC who had urine cytology within 2 months of biopsy, and data were abstracted from their electronic charts. Electronic medical records were reviewed for cystoscopic findings and histologic and cytologic follow-up data over a 5-year period. Statistical analysis was performed with chi-square tests. RESULTS: In total, 76 patients were identified who had histologic follow-up material available, and 49% of those patients demonstrated progression or recurrence of urothelial carcinoma.The initial presence of multiple lesions on cystoscopy was associated with any recurrence or progression (67.7% vs 31%; P ¼ .002), tumor size >2 cm was associated with initial positive or suspicious urine cytology (23.8% vs 3.7%; P ¼ .076), and positive or suspicious initial cytology was associated with high-grade recurrence (58.3% vs 19.4%; P ¼ .009). CONCLUSIONS:Cystoscopic findings, such as the presence of multiple lesions, together with concurrent positive or suspicious urine cytology, were associated with recurrence or progression of LGUC. These findings may help to identify highrisk patients. Cancer (Cancer Cytopathol) 2013;121:398-402.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytologic and cystoscopic predictors of recurrence and progression in patients with low‐grade urothelial carcinoma

Jackson

Barkan

Kapur

et al. 2013

Cancer Cytopathology

View full text Add to dashboard Cite

show abstract

“…Approximately 90% of bladder tumors arise from the urothelial lining, and urothelial carcinoma or transitional cell carcinoma, is the most common histologic type in the United States. Between 50% and 70% of patients with superficial tumors will develop new superficial transitional cell carcinoma, often within 12 months of diagnosis, and 10% to 20% progress to infiltrate muscularis propria (2). Because these tumors have a very high incidence of recurrence, the psychological and economic burdens to the health care system of repeated diagnostic evaluations and therapy are substantial.…”

Section: Introductionmentioning

confidence: 99%

Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in anin vitrobladder cancer carcinogenesis model

Jin¹,

Iwata

Belldegrun

et al. 2006

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Alteration of actin remodeling is a marker of malignantassociated field defect and a potential surrogate biomarker for chemoprevention trials. We tested erlotinib, a specific tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), on actin remodeling in a bladder carcinogenic model consisting of untransformed HUC-PC cells and transformed MC-T11 cells, both derived from the same normal human urothelial clone immortalized by SV40. Erlotinib had a selective growth inhibitory and actin remodeling effect on MC-T11 cells over HUC-PC cells, as examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and immunofluorescence labeling with laser scan cytometer analysis, respectively. The IC 50 of untransformed HUC-PC cells was significantly higher than that of transformed MC-T11 cells (P < 0.05, t test). The actin remodeling effect was more prominent at lower dosage levels (1/8-1/4 of IC 50 ), which was accompanied by an increased cell adhesion and decreased motility. At higher dosage levels (1/2 of IC 50 ), erlotinib induced a decreased adhesion and anoikis (detachmentassociated apoptosis). The transformed MC-T11, but not HUC-PC, showed a weak constitutive EGFR phosphorylation activity, which was inhibited by erlotinib in a doseresponse manner. However, on epidermal growth factor stimulation, both cell lines showed a similar dose-response inhibitory effect on phosphorylated EGFR and mitogenactivated protein kinase (MAPK; P44/P42) activities, and MAPK inhibitor PD98059 showed no specific effect on erlotinib-induced actin remodeling, suggesting that pathways other than MAPK (P44/P42) may be responsible for erlotinib-induced actin remodeling. The findings provide evidence to support erlotinib-based bladder cancer chemoprevention and using actin remodeling as a marker for erlotinib-based intervention trials.

show abstract

“…Although state-of-the-art TUR by itself can eradicate Ta, T1 tumours completely, these tumours commonly recur and can progress to muscle invasive (MIBC) (Witjes, 2009). 85% of patients will relapse, mainly during the first postoperative year (Heney et al, 1982;Dalesio et al, 1983;Torti et al, 1987;Gkritsios et al, 2013). Many recurrences are probably new tumors derived from urothelial dysplastic areas, but a significant proportion can be derived from tumour cells released during resection and eventually implanted in the injured areas (McDonald et al, 1956;Weldon et al, 1975;Page et al, 1978;Soloway et al, 1980;Hyacinthe et al, 1995;Selman et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Postoperative Bladder Irrigation with Water for Injection in Reducing Recurrence Rates of Non Muscle Invasive Bladder Cancer

Grivas¹,

Hastazeris²,

Kafarakis³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Ta and T1 Bladder Cancer: Location, Recurrence and Progression†

Cited by 162 publications

References 14 publications

Cytologic and cystoscopic predictors of recurrence and progression in patients with low‐grade urothelial carcinoma

Cytologic and cystoscopic predictors of recurrence and progression in patients with low‐grade urothelial carcinoma

Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in anin vitrobladder cancer carcinogenesis model

Efficacy of Postoperative Bladder Irrigation with Water for Injection in Reducing Recurrence Rates of Non Muscle Invasive Bladder Cancer

Contact Info

Product

Resources

About